SOAT1 and chronic neutrophilic leukemia: A JAK 1/2 inhibitor, ruxolitinib, has the ability to suppress the oncogenic JAK-STAT pathway signaling and could, therefore, produce therapeutic value in the management of CNL [4-6,11].